Effects of the combined administration of risedronate and menatetrenone on bone loss induced by tacrolimus in rats.
Sign Up to like & getrecommendations! Published in 2020 at "Drug discoveries & therapeutics"
DOI: 10.5582/ddt.2020.03012
Abstract: Tacrolimus, a calcineurin inhibitor, affects bone metabolism and increases the risk of fracture due to marked bone loss. Bisphosphonates increase the bone mineral density (BMD) in osteoporosis patients. Menatetrenone has less positive effects on BMD… read more here.
Keywords: tacrolimus; bone; risedronate; combined administration ... See more keywords